Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Chronic Spontaneous and Inducible Urticaria (Real-World Cohort)
ChiCTR2600123502Phase 4Not yet recruiting
- Sponsor
- Hangzhou Third People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remibrutinib in chronic idiopathic urticaria (CIU) and chronic inducible urticaria (CIndU) (2 arms), sponsored by Hangzhou Third People's Hospital. Primary endpoint: Proportion of patients achieving UCT ≥ 12 at week 12. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on ChiCTR2600123502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123502.